{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:14:17Z","timestamp":1788491657496,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Recent data from clinical trials have shown that neoadjuvant therapies significantly improve the pathological outcomes of prostate cancer patients. This study aimed to assess the specific pathological and prognostic effects of these therapies in a real-world, multicenter cohort. Additionally, we explored how factors such as the duration of neoadjuvant therapy and pretreatment imaging modality impact overall treatment outcomes within this therapeutic framework. Data were collected from 407 patients with locally advanced prostate cancer (LAPC) who underwent radical prostatectomy following neoadjuvant therapy. Kaplan-Meier estimates were used to evaluate the four primary clinical endpoints. The log-rank test was used to assess whether significant differences existed between patients grouped according to neoadjuvant therapy duration and pretreatment imaging modality. After a median follow-up period of 36 months, the median progression-free survival (PFS) for the entire cohort was 19 months. An analysis of different durations of neoadjuvant therapy revealed that compared with a 3-month regimen, a 6-month regimen was significantly associated with a greater extent of pathological downstaging and more favorable values for drug response indicators (Pearson test,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.018). Additionally, the 6-month regimen significantly improved the clinical endpoints of PFS (log-rank test,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.0075) and metastasis-free survival (MFS; log-rank test,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.0069). Kaplan-Meier analysis of patients grouped according to preoperative imaging modality revealed that the use of\n                    <jats:sup>68<\/jats:sup>\n                    Ga-labeled prostate-specific membrane antigen-directed positron emission tomography\/computed tomography (\n                    <jats:sup>68<\/jats:sup>\n                    Ga-PSMA PET\/CT) before treatment, as opposed to traditional imaging, led to significant improvements in the clinical endpoints of PFS (log-rank test,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.0059) and radiographic progression-free survival (rPFS; log-rank test,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.016).\n                  <\/jats:p>","DOI":"10.4103\/aja202530","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:00:31Z","timestamp":1751400031000},"page":"109-116","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Locally advanced prostate cancer treated with neoadjuvant therapy combined with surgery: a multicenter retrospective cohort analysis"],"prefix":"10.4103","volume":"28","author":[{"given":"Shu-Jun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China"},{"name":"Department of Urology, National Region Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China"},{"name":"Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 51000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Jin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 32500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Feng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China"},{"name":"Institute of Urology, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China"},{"name":"Institute of Urology, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Feng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China"},{"name":"Institute of Urology, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 51000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 32500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China"},{"name":"Department of Urology, National Region Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China"},{"name":"Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Qian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China"},{"name":"Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China"},{"name":"Institute of Urology, Nanjing University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Long","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China"},{"name":"Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China"},{"name":"Institute of Urology, Nanjing University, Nanjing 210008, China"},{"name":"Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"R1-20260122","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20260122","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R3-20260122","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study","volume":"63","author":"Rider","year":"2013","journal-title":"Eur Urol"},{"key":"R4-20260122","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20260122","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/pcan.2016.40","article-title":"The very-high-risk prostate cancer:a contemporary update","volume":"19","author":"Mano","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R6-20260122","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R7-20260122","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20260122","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/pros.24184","article-title":"Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores","volume":"81","author":"Wenzel","year":"2021","journal-title":"Prostate"},{"key":"R9-20260122","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1:screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R10-20260122","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R11-20260122","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2009.05.001","article-title":"Adjuvant hormone therapy for localised and locally advanced prostate carcinoma:a systematic review and meta-analysis of randomised trials","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"R12-20260122","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","article-title":"Neoadjuvant endocrine therapy in clinical practice:a review","volume":"7","author":"Sella","year":"2021","journal-title":"JAMA Oncol"},{"key":"R13-20260122","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Goup B 90203 (Alliance):radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"R14-20260122","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2022.03.031","article-title":"Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer:a systematic review and meta-analysis","volume":"82","author":"Rajwa","year":"2022","journal-title":"Eur Urol"},{"key":"R15-20260122","doi-asserted-by":"crossref","first-page":"906370","DOI":"10.3389\/fonc.2022.906370","article-title":"Neoadjuvant chemohormonal therapy in prostate cancer before radical prostatectomy:a systematic review and meta-analysis","volume":"12","author":"Ge","year":"2022","journal-title":"Front Oncol"},{"key":"R16-20260122","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/JU.0000000000003876","article-title":"A prospective randomized trial of neoadjuvant chemohormonal therapy versus hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy","volume":"211","author":"Qian","year":"2024","journal-title":"J Urol"},{"key":"R17-20260122","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/jpm13040641","article-title":"Neoadjuvant androgen receptor signaling inhibitors before radical prostatectomy for non-metastatic advanced prostate cancer:a systematic review","volume":"13","author":"Yanagisawa","year":"2023","journal-title":"J Pers Med"},{"key":"R18-20260122","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual:continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R19-20260122","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","article-title":"Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localizedprostate cancer:results of a pooled analysis of contemporaryclinical trials","volume":"205","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"R20-20260122","first-page":"CD006019","article-title":"Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"2006","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-20260122","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/jcp.55.7.508","article-title":"Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer","volume":"55","author":"Selli","year":"2002","journal-title":"J Clin Pathol"},{"key":"R22-20260122","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","article-title":"Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy:biochemical and pathological effects","volume":"166","author":"Gleave","year":"2001","journal-title":"J Urol"},{"key":"R23-20260122","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"R24-20260122","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","article-title":"68Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer","volume":"70","author":"Herlemann","year":"2016","journal-title":"Eur Urol"},{"key":"R25-20260122","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"key":"R26-20260122","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer:report from the advanced prostate cancer consensus conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"R27-20260122","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1055\/a-0856-6545","article-title":"Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer","volume":"50","author":"Maxeiner","year":"2019","journal-title":"Aktuelle Urol"},{"key":"R28-20260122","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer:a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"key":"R29-20260122","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.euo.2023.09.002","article-title":"Local therapy on clinically lymph node-positive prostate cancer:a systematic review and meta-analysis","volume":"7","author":"Yaow","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:07Z","timestamp":1786647247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202530","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2025-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}